Language
English
عربي
Tiếng Việt
русский
français
español
日本語
한글
Deutsch
हिन्दी
简体中文
繁體中文
Home
How To Use
Language
English
عربي
Tiếng Việt
русский
français
español
日本語
한글
Deutsch
हिन्दी
简体中文
繁體中文
Home
Detail
@carlafayyy:
carla
Open In TikTok:
Region: DE
Friday 15 November 2024 14:39:55 GMT
39058
4439
13
730
Music
Download
No Watermark .mp4 (
0.92MB
)
No Watermark(HD) .mp4 (
1.45MB
)
Watermark .mp4 (
0.97MB
)
Music .mp3
Comments
SAPTA :
idaman..🥰
2024-11-17 04:21:35
0
angellaaa :
😍😍😍
2024-11-15 15:34:04
3
JD :
😍😍
2024-11-15 15:58:35
1
Fer. :
@Oʀᴇᴏ 𝙆𝙞𝙡𝙇𝙚𝙍²³✔️ wolooooo
2024-11-30 13:34:35
1
isetz :
cantik banget kak
2024-11-29 02:01:58
0
Noiy.🐣 :
😁😁😁
2024-11-16 18:57:42
0
aldi pasaribu :
komen ah
2024-11-16 13:04:40
0
EoSPAW :
🥰
2024-11-16 12:32:52
0
akbar maula fachreza :
🥰🥰
2024-11-16 12:28:01
0
celakaku :
tidurrr wee jngn ngebayangin yg ga pastii
2024-11-15 16:11:03
0
sujarwo :
🥰🥰🥰🥰🥰🥰🥰🥰🥰
2024-11-15 15:03:49
0
star *01* :
cantik 🥰🥰🥰🥰
2024-11-15 14:53:33
0
To see more videos from user @carlafayyy, please go to the Tikwm homepage.
Other Videos
The cutest baby ever omg ☺️☺️ #sportsphotography #fentysuperbrandday #photography #photographytips #womeninsports #baby #babygirl #babiesoftiktok #basketball #collegebasketball #basketballphotography #photography #sportsvideo
she said “enough”✋🏽#tiktok #foryou Part 3-telling her another joke, posted!!! Contact
[email protected]
to license
decretado esta #tpashow #risa #paratiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii #fyppppppppppppppppppppppp #🍑 #infielestiktok
Quieren que les cuente cuanto me pagaron por mi primera campaña? #contentcreator #latinainfluencer
#parati insta Daimarrico😍
Two big study updates presented at ESMO on adjuvant ribociclib and abemaciclib (CDK 4/6 inhibitors) in early stage breast cancer. All explained in my Substack. Go to drteplinsky.substack.com. Bottom line if you just want the cliff notes: ⭐️ Ribociclib (Kisqali): At a median follow-up of 55.4 months, absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib+ET). ⭐️ Abemaciclib (Verzenio): 7 year overall survival was 86.8% with abemaciclib-ET and 85.0% with ET (absolute difference, 1.8%). This translates into a 15.8% lower risk of death with abemaciclib + endocrine therapy compared to endocrine therapy alone. Invasive disease free survival was improved by 6.5% at the 7 year mark with the addition of abemaciclib. Additionally, there is a significant difference in the numbers of patients who have developed a distant recurrence and are being treated for metastatic disease (there are 33% fewer patients living with metastatic disease: 180 vs 266 in the group treated with abemaciclib). Over time, this may lead to a further reduction in death from breast cancer. For all the details and nuanced info, check out the substack! @esmo_eur_oncology #esmo25 #cdk #breastcancer #kisqali #verzenio
About
Robot
Legal
Privacy Policy